Although a number of studies reported the association of HLA-DRB1 and Crohn's disease (CD), the actual alleles associated with CD are considerably variable among populations. On the other hand, the relevance of tumor necrosis factor ␣ (TNF␣) in the pathogenesis of CD is established through experimental as well as clinical studies, raising the possibility that TNFA polymorphism is primarily or independently contribute to the association of HLA region genes with CD. New polymorphisms which may affect the transcriptional activity were recently reported within the upstream promoter region of TNFA gene. In the present study, we compared HLA-DRB1, TNFA promoter and TNF receptor 2 (TNFR2) genotypes in 154 Japanese patients with CD and 265 unrelated healthy controls to evaluate the individual contribution of these genes to the genetic predisposition to CD. Significant positive association was observed in HLA-DRB1*0405 (P = 0.001, odds ratio (OR) = 2.02) and 0410 (P = 0.002, OR = 4.79). Among the TNFA promoter haplotypes, TNFA-U03 (−1031C, −863A, −857C) was significantly increased (P = 0.008, OR = 1.64), while TNFA-U04 (−1031C, −863C, −857C) was significantly decreased (P = 0.014, OR = 0.12), in CD. The association with TNFA-U03 was independent of that with DRB1*0405 and 0410, and apparent additive or multiplicative effect was not observed between these susceptibility alleles. No association was observed between TNFR2-196M/R polymorphism and CD. These results indicated that both of HLA-DRB1 and TNFA promoter polymorphisms contribute to the susceptibility to CD in an independent manner. Genes and Immunity (2000) 1, 351-357. 
Introduction
Although the pathogenesis of Crohn's disease (CD) is poorly understood, strong familial clustering ( s = 36.5) 1 as well as increased concordance among monozygotic twins 2 indicates considerable contribution of genetic factors. Susceptibility loci suggested from the genome-wide analyses have been mapped on chromosomes 1, 3, 4, 6, 7, 10, 12, 16, 22 and X. [3] [4] [5] [6] A number of studies examined the association of HLA-DRB1 with CD as one of the strong candidate genes; however, the reported association of HLA genes with CD is variable among populations. For example, positive association of DRB1*01 and 07, as well as negative association of DRB1*03, was reported in the French and German populations. 7, 8 On the other hand, positive association of DRB3*0301-DRB1*1302 haplotype was reported in the Caucasians in the United States. 9 In con-trast, positive association of DRB1*0405, 0410 and negative association of DRB1*1302, 1501 and 1502 with CD have been reported in the Japanese. 10, 11 Tumor necrosis factor ␣ (TNF␣) is a potent proinflammatory cytokine. Several lines of evidence indicated substantial contribution of TNF␣ to the pathogenesis of CD. Increased TNF␣ production has been observed in intestinal mucosa from patients with CD. [12] [13] [14] Moreover, recent clinical trials of monoclonal antibody to TNF␣ demonstrated therapeutic effect in the patients with CD, which provided direct evidence for the pivotal role of TNF␣. 15 The human TNF␣ gene, TNFA, is located within the class III region of the major histocompatibility complex (MHC), 250 kb centromeric to HLA-B and 850 kb telomeric to HLA-DR. Such a chromosomal position as well as the functional relevance raised the possibility that the observed association of CD with HLA-DRB1 may partially be contributed from polymorphisms within the TNFA gene.
Polymorphisms of 5Ј-flanking region of the TNFA gene at positions −238 (G/A) and −308 (G/A) have been reported, and their disease assoiations have been extensively studied. 16 −308A allele has been shown to be associated with high promoter activity, 17 and several studies have thus far examined association of TNFA-308A with CD; however, the results are inconsistent. 16, [18] [19] [20] [21] A recent study reported the association of −308A allele with higher TNF␣ production in the patients with CD, but the presence of −308A was not significantly associated with the susceptibility to CD. 22 In contrast, some of the recent studies reported linkage of microsatellite markers located close to the TNFA and TNFB loci with CD. 23, 24 Taken together, these observations suggest the possibility that TNFA promoter polymorphisms other than −308 and −238 may contribute to the susceptibility to CD. New single nucleotide polymorphisms (SNPs) at positions −1031 (T/C), −863 (C/A) and −857 (C/T) were recently identified in the upstream 5Ј-flanking region of human TNFA. 25, 26 Although −308A and −238A alleles are rare in Japanese, each of the upstream SNPs was found in a substantial proportion of the Japanese population. 25 Moreover, some of the alleles were shown to have higher promoter activity as compared with others. 25 A recent study actually reported that TNFA −1031C, −863A, and −857T are positively associated with CD in the Japanese population. 27 However, whether these SNPs are independently associated with CD or they merely reflect linkage disequilibrium with HLA-DRB1 was not analyzed.
Another line of evidence suggesting the potential relevance of TNF signaling pathway in CD has recently been reported. One of the genome-wide linkage screenings suggested the chromosomal region near 1p36 to be a candidate region for CD. 5 The gene encoding one of the receptors for TNF, TNF receptor II (TNFR2, TNF-R75), is located at 1p36.2. No study has been reported concerning the association of TNFR2 polymorphism with CD.
We have recently established a single-step genotyping method for TNFA −1031/−863/−857 SNPs, and demonstrated that four haplotypes, TCC, TCT, CAC and CCC, designated TNFA-U01, U02, U03 and U04, respectively, account for the most, if not all, of the genotypes in the Japanese population. 28 In addition, TNFA promoter haplotypes were found to form multi-locus haplotypes with HLA-A, B and DRB1 genes. 28 As for TNFR2, we demonstrated that the allele coding for a substitution of R for M at position 196 (196R) is significantly associated with systemic lupus erythematosus (SLE). 29 Based on such observations, we considered that the association of HLA with various diseases needs to be reevaluated in terms of TNFA promoter polymorphism. Furthermore, genotypes of HLA-DRB1, TNFA promoter and TNFR2 should be analyzed at the same time to examine whether any of these genes contributes independently, through linkage disequilibrium with, or in combination with another gene. In such an approach, we recently analyzed these genotypes in a large number of Japanese patients with rheumatoid arthritis, and reported that, among the three genes, association with HLA-DRB1 seems to be primary. 30 The same strategy can appropriately be applied to dissect the previously reported association of HLA-DRB1 and TNFA promoter alleles in CD.
In the present study, we determined the genotypes of HLA-DRB1, TNFA promoter and TNFR2 codon 196 in the Japanese patients with CD and healthy controls, and made an attempt to examine whether polymorphism of TNFA promoter or TNFR2 contributes to the susceptibility to CD independently, or through interaction with HLA-DRB1 genotypes.
Results

HLA-DRB1 genotypes
The positivity of each HLA-DRB1 allele among the patients and controls is shown in Table 1 . 'Positivity' was defined as the percentage of individuals carrying at least one allele or haplotype. Significant positive association with CD was observed in DRB1*0405 (P = 0.001, Pc = 0.021, odds ratio (OR):2.02, 95% confidence interval (CI): 1.32-3.08) and in DRB1*0410 (P = 0.002, Pc = 0.042, OR: 4.79, 95% CI: 1.83-12.6). DRB1*1101 (P = 0.014, OR:4.00, 95% CI:1.47-10.9) was shown to be slightly increased in CD, although the P-value was not significant after correction for the number of comparisons.
In contrast, DRB1*0901 (P = 0.044, OR: 0.62, 95% CI: 0.38-0.99) and DRB1*1302 (P = 0.028, OR: 0.52, 95% CI: 0.29-0.93) were slightly decreased in CD, but the P-value was not significant after correction ( Table 1) .
The difference in the overall distribution of HLA-DRB1 positivity was highly significant between the patients and controls ( 2 = 59.6. P Ͻ 0.0001, df = 21).
TNFA promoter genotypes
The genotype and haplotype frequencies of TNFA promoter are listed in Table 2 . The haplotype frequency of TNFA-U03 was significantly increased in the patients (20.8%) as compared with healthy controls (13.8%) (P = 0.008, Pc = 0.024, OR: 1.64, 95% CI: 1.14-2.37). On the other hand, the haplotype frequency of TNFA-U04 was significantly decreased in the patients (P = 0.014, Pc = 0.042, OR: 0.12, 95% CI: 0.02-0.82). TNFA-U01 was also slightly decreased in the patients. Similar tendency was observed for the haplotype positivity (Table 2 ), although the difference was less significant, suggesting the presence of gene dosage effect.
Since HLA-DRB1 and TNFA genes are in linkage disequilibrium, it was possible that the observed association of either one of the two genes might be simply caused by the primary association of the other. To dissect the individual contribution of these genes, the combination of the genotypes of these genes was compared in the patients and controls. The results are summarized in Table 3 . Association with TNFA-U03 with CD remained significant in individuals negative for DRB1*0405 or DRB1*0410 (Table 3 , group C vs D). Similarly, association of HLA-DRB1 alleles with CD remained significant in individuals negative for TNFA-U03 (group B vs D). These results indicated that both TNFA-U03 and HLA-DRB1* 0405 and 0410 contribute to the susceptibility to CD in an independent manner. Interestingly, significant difference in the odds ratio was not observed between individuals possessing susceptibility alleles in both loci (group A vs D) and in only one of the loci (group B vs D, C vs D), indicating that multiplicative or additive effect is not present between the two loci. Thus, the presence of TNFA-U03 did not give additional risk of CD among DRB1*0405 or *0410 positive individuals (group A vs B).
In total, 69.5% of the patients possessed at least one of the susceptibility alleles in these two loci, compared with 44.2% of the controls (P Ͻ 0.0001, OR = 2.88, 95% CI: 1.90-4.36).
Lack of association with clinical subsets
The independent association of HLA-DRB1 and TNFA, as well as the lack of additive effect between the two, raised (Table 4) .
TNFR2-196M/R genotypes
The frequency of TNFR2 codon 196 polymorphism is shown in Table 5 . No significant association with CD was observed. In order to test possible interaction with TNFA promoter polymorphisms, the patients and controls were 
Discussion
In the present study, through the genotyping of HLA-DRB1, TNFA upstream promoter region and TNFR2, an attempt was made to evaluate the contribution of these genes to the susceptibility of CD in a separate manner. The results indicated that, HLA-DRB1 and TNFA promoter polymorphism independently contributed to the susceptibility, while no association was observed between TNFR2 polymorphism at codon 196 and CD. To our knowledge, this is the first direct evidence for the independent association of HLA-DRB1 and TNFA upstream promoter polymorphisms with CD. Our present data confirmed previous reports which indicated the positive association of DRB1*0405 and 0410, as well as the tendency of negative association of DRB1* 1302 and 1502, in Japanese. 10, 11 Although the linkage of CD to the MHC region has been repeatedly reported, 6, 24, 30 considerable variations are present in the actual HLA-DRB1 alleles associated with CD among the populations. [7] [8] [9] [10] [11] Such discrepancy suggested that the role of HLA-DRB1 may not be primary for the pathogenesis of CD. In this context, the linkage of microsatellite markers within the TNF region, 23, 24 and clinical relevance of TNF␣ in CD [12] [13] [14] [15] raised the possibility that TNFA promoter polymorphism may actually contribute primarily to the genetic predisposition of CD. Our present data actually provide evidence for the association of TNFA-U03. Of interest, HLA-DRB1*0901, which forms a haplotype with TNFA-U03 in the healthy Japanese population, 28 was found to be slightly decreased in the patients (Table 1) . On the other hand, HLA-DRB1*0405, which was significantly associated with CD, forms a haplotype with TNFA-U02 in healthy Japanese. 28 These observations suggested that the association of DRB1*0405, 0410 and that of TNFA-U03 with CD are independent of each other. Such a possibility was actually found to be the case, using stratification analysis. Independent contributions of HLA-class II and TNF loci have also been demonstrated in other chronic inflammatory disorders such as rheumatoid arthritis 31, 32 and systemic lupus erythematosus. 33 Interestingly, the susceptibility alleles of HLA-DRB1 and TNFA were not shown to act in an additive or multiplicative manner. Such a finding suggested the possibility that the patients with susceptible HLA-DRB1 alleles and those with susceptible TNFA haplotype may represent two different clinical subsets. Although these genotypes were not found to be associated with clinical symptoms such as perforation and requirement of surgery, such clinical outcome measures are considered to be suboptimal, and other clinical phenotypes needs to be analyzed in the future. Furthermore, this stratification analysis excluded the possibility that a unique haplotype formed by DRB1*0405 or 0410 and TNFA-U03 is present only in the patients.
Another new finding in this study is the significant negative association of TNFA-U04 with CD. Since at least two SNP sites (−1031 and −863 or −857) need to be genotyped to determine this haplotype using conventional methods, our single-step typing system is especially useful for the detection of this haplotype. 28 TNFA upstream promoter region −1031C, −863A and −857T were recently reported to be associated with CD in Japanese. 27 TNFA-U03 encodes −1031C and −863A, whereas −857T is encoded by TNFA-U02. 28 Although the difference did not reach statistical significance, we also found slight increase of TNFA-U02 in CD. Thus, our study essentially confirmed their observation at the allele level. This slight increase of TNFA-U02 was probably caused by linkage disequilibrium with DRB1*0405, 28 which is primarily associated with CD.
Regarding the promoter activity of TNFA promoter haplotypes, inconsistent results have been reported by three separate studies. While Higuchi et al 25 demonstrated elevated promoter activity of TNFA-U02 and -U03, 25 Uglialoro et al 26 reported no difference, and Skoog T et al 34 reported lower activity of TNFA-U03. Such a difference may probably be related to the difference in the types of cells and experimental systems. Increased frequency of TNFA-U03 and -U02 in CD is considered to be consistent with elevated promoter activity of these haplotypes, although further studies are required to draw a definite conclusion. Similarly, TNFA-U04 and -U01 have been shown to be associated with lower production of TNF␣, 25 which is consistent with the decreased frequency in CD observed in this study.
TNFR2 polymorphism was examined because of the functional relevance of TNF␣ in CD, and also because recent genome-wide screening reported chromosomal region 1p35-36 as one of the candidate susceptibility to CD. 5 To our knowledge, this is the first study which tested the possible association of a SNP within the TNFR2 coding sequence and CD. Although a significant association was not observed, the results also need to be analyzed in terms of the interaction with chromosome 16 susceptibility locus (IBD1) in the future, since interaction between 1p and IBD1 has been demonstrated from the linkage analysis.
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In conclusion, the present study provided the first comparative data on the individual role of HLA-DRB1, TNFA promoter and TNFR2 genes for the susceptibility to CD. Further studies on the patients and controls in various populations, as well as the functional analyses, will provide valuable information for the determination of relative contribution of these genes to the development of CD.
Materials and methods
Patients and healthy individuals
Genotyping of HLA-DRB1, TNFA upstream promoter region and TNFR2 was performed on 154 patients with CD, who had been followed up in the Division of Gastroenterology, Social Health Insurance Medical Center (Tokyo, Japan). All patients were Japanese and unrelated to each other. A total of 124 patients were male, and 30 were female. Their mean age was 31.1 years. The patients were classified according to presence or absence of perforation and history of surgical treatments.
The control group consisted of 265 healthy laboratory personnel or students, 145 of them were male and 120 were female. All of them were Japanese, unrelated individuals living in Tokyo area. Their mean age was 39.9 years. HLA-DRB1, TNFA promoter and TNFR2-196M/R genotypes of the control group were previously been reported. 30 The central part of Japan has been shown to be relatively homogeneous with respect to the genetic background, 35 permitting the case-control approach employed in this study.
Genomic DNA
Genomic DNA from patients and healthy individuals was purified from peripheral blood leukocytes using the QIAamp blood kit (Qiagen, Hilden, Germany).
TNFA promoter genotyping using PCR-preferential homoduplex formation assay (PHFA) Genotyping of TNFA -1031, -863 and -857 SNPs was carried out at the haplotype level, using PCR-PHFA, which was described in detail separately. 28 Briefly, cloned DNA corresponding to each of the four alleles of TNFA promoter was amplified by PCR using biotin-labeled forward primer (5Ј-TGGACTCACCAGGTGAGGCC-3Ј) and DNP-labeled reverse primer (5Ј-TCACTCCCTGGGG CCCTCTA-3Ј), and was used as the standard. Sample DNA was also amplified by PCR using the unlabeled primers with the same nucleotide sequences. PCR was carried out using GeneAmp reagents and AmpliTaq Gold DNA polymerase (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). The amplification conditions consisted of initial denaturation at 96°C for 10 min, followed by 40 cycles of denaturation at 96°C for 30 s, annealing at 58°C for 30 s, and extension at 72 C for 1 min, using a thermal cycler (GeneAmp PCR system 9600; PerkinElmer Applied Biosystems). Subsequently, hybridization was performed in 30 l of reaction mixture containing 0.25 l of labeled amplicon, 10 l of unlabeled amplicon, and 4.5 l of 20 × SSC (3 m NaCl, 0.3 m sodium citrate). The mixture was denatured at 98°C for 10 min, then slowly cooled to 80°C at a rate of 1°C per 10 min, using GeneAmp PCR system 9600 (Perkin-Elmer). Subsequently, 20 l of hybridization mixture was transferred to a streptavidin-coated microtiter well containing 100 l of anti-DNP antibody conjugated alkaline phosphatase in solution I (1 m Tri-HCl (pH 7.5), 1 m NaCl, 20 mm MgCl 2 , and 0.5% Triton-X). After incubation for 30 min, the mixture was aspirated and the well was washed three times with solution I. Thereafter, 100 l of chromogenic substrate solution, 40 g/ml pNPP (sodium pnitrophenylphosphate), in diethanolamine buffer (1 m diethanolamine, 0.5 mm MgCl 2 ), was added to each well. The coloring reaction proceeded for 15 min and the absorbance at 405 nm was read.
Genotyping of TNFR2-196M/R and HLA-DRB1
TNFR2-196M/R alleles were determined using PCRsingle strand conformation polymorphism (SSCP) method, as previously described. 29 HLA-DRB1 alleles were determined at the sequence level using PCRmicrotitre plate hybridization assay, as previously described.
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Statistical analysis
The genotype frequency, allele or haplotype frequency and positivity, defined as the percentage of individuals carrying at least one allele or haplotype, were compared between CD patients and healthy controls using the 2 test or Fisher's exact test. Correction for the multiple comparisons was done by multiplying the P value by the number of comparisons (Pc). P-values Ͻ0.05 were regarded as statistically significant.
